According to the Zhitong Finance APP, *ST Dayao (603963.SH) announced that the trading price of the company's Stocks has recently fluctuated significantly. The company's main Business is the production and sales of Traditional Chinese Medicine injections and Pharmaceutical Commerce distribution. As of now, there has been no significant change in the direction of the main Business.

Due to the impact of policies related to the centralized procurement of Chinese Patent Medicine, the sales volume of Traditional Chinese Medicine injections has continued to decline, and the revenue scale of the Pharmaceutical Commerce distribution business is relatively small, resulting in an overall decline in the main Business from January to September. From January to September 2024, the company achieved revenue of 47.6474 million yuan, a decrease of 34.97% compared to the same period last year; the Net income attributable to Shareholders of the listed company was -19.7351 million yuan; and the Net income attributable to Shareholders of the listed company, after deducting non-recurring gains and losses, was -22.4036 million yuan, which poses a risk of potentially triggering financial (Delisted).